{"id":"NCT03170271","sponsor":"AstraZeneca","briefTitle":"A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.","officialTitle":"A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients With Severe Asthma Uncontrolled on Standard of Care Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-07","primaryCompletion":"2019-09-25","completion":"2020-10-21","firstPosted":"2017-05-31","resultsPosted":"2020-12-16","lastUpdate":"2021-11-01"},"enrollment":660,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Benralizumab (Medi-563)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Benralizumab (Medi-563)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to investigate the effect of benralizumab on the rate of asthma exacerbations, patient reported quality of life and lung function during the 24-week treatment in patients with uncontrolled, severe asthma with an eosinophilic phenotype. A subset of patients will be assessed for their ongoing chronic rhinosinusitis with nasal polyps. The study design has been updated to include a 56-week open label ANDHI in Practice (ANDHI IP) sub study upon the completion of the 24-week double-blind period of the ANDHI study.","primaryOutcome":{"measure":"Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24)","timeFrame":"Baseline (Week 0) up to Week 24","effectByArm":[{"arm":"Benralizumab","deltaMin":0.94,"sd":null},{"arm":"Placebo","deltaMin":1.86,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":213,"countries":["United States","Austria","Belgium","Canada","Denmark","Finland","France","Germany","Italy","Netherlands","Norway","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["36948488","33710614","33357499"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00045&amp;attachmentIdentifier=9ee3eb1e-53ba-4b2b-8800-1dd44269f23a&amp;fileName=D3250C00045_CSP_v4.0_Final_22SEP20_Redacted_PDFA.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00045&amp;attachmentIdentifier=b0e85ad9-7be7-42a2-ace7-8aa882732f3a&amp;fileName=D3250C00045_SAP_ed3.0_Final_22SEP20_Redacted_PDFA.pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D3250C00045&amp;attachmentIdentifier=b445a28c-2828-42a1-813d-19218e2ca383&amp;fileName=D3250C00045-CSR_synopsis-ANDHI_Main_Final_Redacted_19Oct21_PDFA.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":427},"commonTop":["Nasopharyngitis","Headache","Bronchitis","Sinusitis","Pyrexia"]}}